45
Participants
Start Date
May 21, 2018
Primary Completion Date
November 3, 2021
Study Completion Date
May 2, 2024
Nivolumab
Nivolumab is a human programmed death receptor-1 (PD-1) antibody currently approved in different diseases.
Capecitabine
Capecitabine was selected for Arm B given the recent results from CREATE-X trial and the increasing use by the community (feasibility). Importantly, available data from other scenarios indicates that capecitabine does not have immunosuppressive effects
MedStar Georgetown University Hospital, Washington D.C.
MedStar Washington Hospital Center, Washington D.C.
University of Chicago, Chicago
John Theurer Cancer Center at Hackensack University Medical Center, Hackensack
Collaborators (1)
Bristol-Myers Squibb
INDUSTRY
Georgetown University
OTHER